Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 2013 May 21;110(21):8680-5. doi: 10.1073/pnas.1301190110. Epub 2013 May 7.

Engineering bone tissue substitutes from human induced pluripotent stem cells.

Author information

1
The New York Stem Cell Foundation, New York, NY 10032, USA.

Abstract

Congenital defects, trauma, and disease can compromise the integrity and functionality of the skeletal system to the extent requiring implantation of bone grafts. Engineering of viable bone substitutes that can be personalized to meet specific clinical needs represents a promising therapeutic alternative. The aim of our study was to evaluate the utility of human-induced pluripotent stem cells (hiPSCs) for bone tissue engineering. We first induced three hiPSC lines with different tissue and reprogramming backgrounds into the mesenchymal lineages and used a combination of differentiation assays, surface antigen profiling, and global gene expression analysis to identify the lines exhibiting strong osteogenic differentiation potential. We then engineered functional bone substitutes by culturing hiPSC-derived mesenchymal progenitors on osteoconductive scaffolds in perfusion bioreactors and confirmed their phenotype stability in a subcutaneous implantation model for 12 wk. Molecular analysis confirmed that the maturation of bone substitutes in perfusion bioreactors results in global repression of cell proliferation and an increased expression of lineage-specific genes. These results pave the way for growing patient-specific bone substitutes for reconstructive treatments of the skeletal system and for constructing qualified experimental models of development and disease.

KEYWORDS:

bone regeneration; dynamic culture; embryonic stem cells; mesodermal progenitors; microarray analysis

PMID:
23653480
PMCID:
PMC3666730
DOI:
10.1073/pnas.1301190110
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center